Impact of DESTINY-Breast09 and Other Trials on Clinical Practice and Patient Subsets

EP: 1.Challenges in Diagnosing HER2+ Breast Cancer

EP: 2.Neoadjuvant Treatment Options in HER2+ Early Breast Cancer

EP: 3.Preoperative Monitoring and Surgical Options for HER2+ Patients

EP: 4.Clinical Impact of Subcutaneous Fixed-Dose Pertuzumab – trastuzumab-hyaluronidase in HER2+ Breast Cancer

EP: 5.Standard-of-Care Regimens for First-Line Treatment of HER2+ mBC

EP: 6.Ongoing Clinical Trials in HER2+ Metastatic Breast Cancer

Now Viewing

EP: 7.Impact of DESTINY-Breast09 and Other Trials on Clinical Practice and Patient Subsets

EP: 8.Defining HER2 Low and HER2 Ultra-Low: Diagnostic Challenges

EP: 9.Overview of DESTINY-Breast06

EP: 10.Clinical Perspectives on Managing ILD Related to T-DXd

EP: 11.Clinical Considerations and Subsequent Therapies or Sequencing in HER2-Low/HER2+ mBC

EP: 12.Unmet Needs and Future Direction in HER2+ Breast Cancer

Video content above is prompted by the following questions:

• How would the results of the DESTINY-Breast09 trial impact your clinical practice?
• What are your thoughts on the other trials mentioned above if they do result in positive results in PFS? How would they be applied to your treatment of different patient subsets?